<DOC>
	<DOCNO>NCT00947388</DOCNO>
	<brief_summary>This phase I trial study side effect best dose alemtuzumab give together bendamustine hydrochloride treat patient relapse chronic lymphocytic leukemia ( CLL ) small lymphocytic lymphoma ( SLL ) respond fludarabine phosphate . Drugs use chemotherapy , bendamustine hydrochloride , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , alemtuzumab , also block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving bendamustine hydrochloride together alemtuzumab may kill cancer cell .</brief_summary>
	<brief_title>Bendamustine Plus Alemtuzumab Refractory Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Evaluate safety combination alemtuzumab bendamustine ( bendamustine hydrochloride ) patient advanced CLL . II . Establish maximum tolerate dose alemtuzumab standard dose 30mg thrice weekly combine bendamustine standard dose 70 mg/m^2 day 8 9 monthly . III . Define recommend dose subsequent Phase II study . IV . Evaluate preliminary evidence activity determine response rate correlation EAS flow cytometry . OUTLINE : This dose-escalation study alemtuzumab . Patients receive bendamustine hydrochloride intravenously ( IV ) 30-60 minute day 8 9 6 course absence disease progression unacceptable toxicity alemtuzumab subcutaneously ( SC ) day 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 . After completion study treatment , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1 . Patients CLL SLL define WHO classification system indication treatment National Cancer Institute ( NCI ) Working Group criterion . 2 . Measurable disease ( lymphocytes equal great 5,000/µL , measurable lymphadenopathy , bone marrow involvement great 30 % ) . 3 . Males females 18 year age old . 4 . Patients must relapse refractory treat minimum one prior purine analogbased chemotherapy regimen ( e.g. , fludarabine , cladribine , pentostatin ) . 5 . All previous cancer therapy , radiation , hormonal therapy surgery , must discontinue least 28 day prior start treatment . Any cytotoxic chemotherapy must discontinue 28 day prior start treatment . Acute toxicities prior therapy must resolve Grade ≤ 1 baseline . 6 . Normal oxygen saturation pulse oximetry room air . 7 . Hemoglobin 9 great gm/dL ( may posttransfusion ) . 8 . Platelet count 50 x103/mL great 9 . Total bilirubin le 2 X ULN , ALT AST le 2 x ULN . 10 . Serum creatinine 2 X ULN less . In addition , calculate glomerular filtration rate ( GFR ) must &gt; 30cc/min . 11 . ECOG Performance Status 2 less . 12 . Anticipated survival least 3 month . 13 . For men woman childproducing potential , use effective contraceptive method study one month discontinuation treatment . 1 . Pregnant lactating woman . 2 . Severe chronic obstructive pulmonary disease hypoxemia uncorrectable pulmonary compromise . 3 . Seizures control anticonvulsant therapy . 4 . Participation investigational drug study within 28 day study entry . 5 . Patients second malignancy require active treatment . 6 . Active , symptomatic bacterial , fungal , viral infection include active HIV viral ( A , B , C ) hepatitis . 7 . Clinically significant bleeding event within last 3 month , unrelated trauma , underlying condition would expect result bleed diathesis . 8 . Patients life functionthreatening CLL complication ( e.g. , cord compression , hemolytic crisis , urinary tract obstruction ) . 9 . Any illness condition opinion investigator may affect safety treatment evaluation study 's endpoint . 10 . Systemic treatment CLL/SLL within 28 day study entry 11 . Subjects history leukemic meningitis , sign symptom suggestive leukemic meningitis , must negative lumbar puncture within 2 week study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Refractory Chronic Lymphocytic Leukemia</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Phase I</keyword>
	<keyword>CLL</keyword>
</DOC>